Edesa Biotech announced it has received orphan drug designation from the European Commission for its investigational drug, paridiprubart, for the treatment of Acute Respiratory Distress Syndrome (ARDS). This regulatory milestone recognizes the significant unmet medical need for ARDS and provides key development incentives in the European Union.
Key Details
- Designation: The European Commission granted orphan designation for paridiprubart following a positive opinion from the European Medicines Agency (EMA).
- Incentives: The designation provides benefits including reduced development fees, streamlined regulatory interactions, and a potential 10 years of market exclusivity in the EU following approval.
- Supporting Data: The decision was supported by Phase 2/3 clinical data that demonstrated statistically significant improvements in survival for critically ill ARDS patients requiring invasive mechanical ventilation.